Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, and commercial organizations in the United States. The company operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children's health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans. This segment also provides healthcare products and services. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual, small, and large group commercials. The Other segment operates clinical healthcare and pharmacies, as well as offers vision and dental, behavioral health, federal, and corporate management services. It provides services through primary and specialty care physicians, hospitals, behavioral health practitioners, and ancillary providers. The company was founded in 1984 and is headquartered in Saint Louis, Missouri.
Centene's Market Stance | Explore Centene's position in government-sponsored healthcare, its $28B market cap, and how it's navigating industry challenges despite a 24% stock decline |
Financial Projections | Analysts forecast EPS of $7+ for FY2025, with potential to reach $10 by 2027. Price targets range from $84 to $97, suggesting undervaluation |
Regulatory Landscape | Delve into how Medicaid expansion, ACA subsidies, and Medicare changes shape Centene's operating environment and growth strategies |
Growth Opportunities | Learn about Centene's focus on margin improvement, Medicare Advantage expansion, and leveraging its strong position in the dual-eligible market |
Metrics to compare | CNC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCNCPeersSector | |
---|---|---|---|---|
P/E Ratio | 7.9x | 12.8x | −0.4x | |
PEG Ratio | 0.24 | −0.10 | 0.00 | |
Price/Book | 1.0x | 2.3x | 2.6x | |
Price / LTM Sales | 0.2x | 0.9x | 3.0x | |
Upside (Analyst Target) | 33.6% | 31.9% | 52.3% | |
Fair Value Upside | Unlock | 8.1% | 9.4% | Unlock |